Coleman & Company Securities, Inc. Announces Investment Opinion on Generex Biotechnology Corp.NEW YORK--(BUSINESS WIRE)--Oct. 13, 1999-- Coleman & Company Initiates Coverage with a Speculative BUY for Generex Biotechnology Corp. (GNBT) Coleman & Company Securities, Inc., the New York-based investment banking and brokerage firm, has initiated coverage on Generex Biotechnology Corp. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: GNBT) with a "Speculative BUY" recommendation. In a report dated October 13, 1999 by analyst Christopher Moore Christopher Moore may refer to:
n. 1. Orient The countries of Asia, especially of eastern Asia. 2. a. The luster characteristic of a pearl of high quality. b. A pearl having exceptional luster. 3. investors. Generex has developed a proprietary drug delivery platform for the oral administration of large molecule drugs. Its initial focus is the oral delivery of insulin using its proprietary insulin formulation ORALGEN(TM) for the treatment of diabetes. Initial Phase II results have shown that ORALGEN(TM) provides comparable clinical efficacy to injected in·ject·ed adj. 1. Of or relating to a substance introduced into the body. 2. Of or relating to a blood vessel that is visibly distended with blood. injected 1. introduced by injection. 2. congested. insulin. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion